WBC Differential by Flow Cytometry: The First Routine Application in a Large University Hospital Clinical Laboratory.

Blood ◽  
2007 ◽  
Vol 110 (11) ◽  
pp. 3845-3845
Author(s):  
Mikael Roussel ◽  
Cyrille Benard ◽  
Béatrice Ly Sunnaram ◽  
Danielle Gerard ◽  
Jean Feuillard ◽  
...  

Abstract Hematology analyzers deliver high precision blood cell counts and a good leukocyte differential (WBCD) on normal samples. But their ability to identify and quantify abnormal cells is less good and generates a significant amount of false positive results. Routinely, about 10% to 30% of results must have manual blood film reviews, which requires considerable time and are prone to a high degree of inaccuracy, especially for the less frequent cell types (Rümke et al. 1975). In contrast, flow cytometry offers superior detection and quantification of these rare events. A Cyto Diff tube combining six antibodies (CD45, 16, 2, 36, 19 & CRTH2) analysed on a modern multicolor flow cytometer make very accurate automated WBCD feasible for abnormal samples (Feuillard J et al. ISLH 2007). The objective of the study was to evaluate the efficiency of the Cyto Diff process compared to the normal laboratory process as: The time for both methods, the labor and time savings, the relative costs of both methods including med tech time, consumables, number of residual manual review. Two Coulter LH750® hematology analysers were used for the analysis of CBC, WBCD and Reticulocyte counting. An immuno-phenotyping system, with an automatic preparator Coulter FP 1000 and an Coulter FC 500® flow cytometer were connected with a Hematology analyzer to the REMISOL data manager that requests a reflex CytoDiff tube on every sample flagged by the hematology analyzer according to the laboratory’s validation rules. The remaining samples are displayed for manual validation by an operator. The complete line is called HematoFlow. Among the 4896 non-selected CBC tests evaluated during the 10 working days of our study, 877 cases were flagged by the analyzers, reviewed manually following the normal procedure as well as analyzed on HematoFlow. Interestingly, this latter allowed: 68.8% of auto-validation by the REMISOL Data Manager, 12.8% validation directly by the operator after checking the auto-gating, 8.4% required a region readjustment before validation and finally, only 10.3% (91 of the 877-flagged samples) required further exploration because the presence of large amount of ImmGrans, Plt clumps, NRBCs, etc. In conclusion, the CytoDiff tube performs well in regular clinical lab workflow saving almost 90% of the samples flagged by the hematology analyzers for WBC abnormalities that need further exploration following current routine procedure. Our study confirmed our previous results and the fact that the standard auto-gating is set correctly needing only 8.4% of region readjustment by an operator who can be trained easily in few days. Basically, we are expecting that one operator well-trained for smear review and working on the HematoFlow line can handle the same workload as at least 3 operators at microscope stations following a current normal procedure. Furthermore, the CytoDiff approach provides additional information concerning the white blood cells in pathological context never obtained previously by cytomorphology including the detection of likely pro-inflammatory monocytes, several blast subsets, and multiple lymphocyte sub populations as well.

2001 ◽  
Vol 125 (3) ◽  
pp. 391-396 ◽  
Author(s):  
Katharina Ruzicka ◽  
Mario Veitl ◽  
Renate Thalhammer-Scherrer ◽  
Ilse Schwarzinger

Abstract Context.—The new hematology analyzer Sysmex XE-2100 (TOA Medical Electronics, Kobe, Japan) has a novel, combined, white blood cell differential technology and a special reagent system to enumerate nucleated red blood cells. Design.—Performance evaluation of both technologies of the Sysmex XE-2100 according to the H20-A protocol of the National Committee for Clinical and Laboratory Standards and comparison of the results with those for the hematology analyzer Sysmex NE-8000 (TOA Medical Electronics). Specimens.—Five hundred forty-four blood samples randomly chosen from various inpatient and outpatient departments of the Vienna University hospital. Results.—Five-part white blood cell differential counts on the XE-2100 revealed excellent correlation with the manual reference method for neutrophils, lymphocytes, and eosinophils (r = .925, .922, and .877, respectively) and good correlation for monocytes and basophils (r = .756 and .763, respectively). The efficiency rates of flagging for the presence of ≥1% abnormal white blood cells were 83% (XE-2100) and 66% (NE-8000). The correlation of automated and microscopic nucleated red blood cell counts was excellent (r = .97). Conclusions.—From the present evaluation and our former experience with other types of Sysmex analyzers, we conclude that the new white blood cell differential technology of the XE-2100 represents a further development toward more efficient flagging of abnormal white blood cells.


Blood ◽  
2015 ◽  
Vol 126 (23) ◽  
pp. 3099-3099 ◽  
Author(s):  
Thomas Porturas ◽  
Mary Sell ◽  
Leah Irwin ◽  
Una O'Doherty ◽  
Carlos Hipolito Villa

Abstract Background: Although peripheral blood CD34+ stem cell counts by flow cytometry correlate well with yields, the time, complexity, and cost associated with flow cytometry limits its utility. Rapid, cost-effective, surrogate predictors (with <1hr turnaround) would allow for same-visit analyses and alteration of collection and mobilization strategies, particularly for the optimal use of time-sensitive and costly agents such as plerixafor. We previously demonstrated that morphologic parameters of neutrophil-like cells measured by hematology analyzers correlated with CD34 counts. We aimed to improve these models by using multiple regression analyses on data from a common hematology analyzer. Methods: Patients undergoing stem cell apheresis were evaluated over a 6 month period. The day prior to initiation of apheresis, and on the morning of initial collection, peripheral blood samples were drawn into EDTA collection tubes and flow cytometric CD34 measurement and/or CBCs were performed on the Beckman Coulter DxH 800 hematology analyzer per standard protocol. CD34 cells were counted by flow cytometric ISHAGE protocols. Data from the DxH (48 variables per specimen) were exported into a data matrix with the corresponding flow cytometric data. Multiple regression analysis was performed using a step-wise method with log(peripheral CD34) as the dependent variable (SPSS, IBM). Data were randomly selected into a training-set of 70% of cases and a test-set of 30% of cases for validation. The derived model was further tested against peripheral blood data from the morning of collection to predict harvest yields. Further analyses were performed using Prism (GraphPad). Results: Tandem peripheral blood CD34 counts and CBC cell-population data were obtained from 69 blood samples in 64 patients. The population included patients with multiple myeloma (45), non-Hodgkin lymphoma (12), Hodgkin lymphoma (5), and amyloidosis (2). 41% of patients were female. In the test data set examining collection yields, 37 patients were mobilized with GCSF (+/- chemotherapy) alone, while 17 had plerixafor added to the regimen. 33 of these patients had same-day CBC data available for model prediction. The median processed volume was 15 L (range 5.9 to 19.7). The model to predict peripheral CD34 counts incorporated 3 variables from the hematology analyzer data (SD-V-EGC, SD-C-EGC, and NE#). Interestingly, the model included two variables descriptive of the morphology of early granulocytic cells. The model demonstrated an R value of 0.829 (adjusted R2 = 0.670, figure 1a). In testing the morning-of-collection model-predicted peripheral CD34, we found the model performed similarly to flow cytometry in predicting 1st collection yields. Furthermore, the CD34 prediction using the model (Figure 1 b) resulted in similar correlation with first-collection yields in patients treated with plerixafor versus patients not treated with plerixafor, in contrast to day-prior CD34 counts by flow-cytometry (Figure 1c). Two outliers for CD34 cell yield based on model predicted peripheral CD34 were identified. In one patient, the processed volume was very low (6.8 L, <5% percentile), while the second had a low mononuclear cell collection efficiency (35%) compared to the mean in this population (58.7%±23.3%). Threshold values for the model accurately identified patients appropriate for collection initiation (or plerixafor administration). Conclusion: Using data from a common, automated CBC analyzer, we developed a rapid, less-costly, and simple model to predict CD34 cell counts and 1st harvest yields. Because the measurement results can be obtained within the same clinic visit, and can be repeated with each CBC, the model is particularly useful to guide optimal use of plerixafor. We also envision that the model is useful for quality assurance of collection by identifying patients in whom cell yields were sub-optimal with respect to predicted CD34 cell counts. Additional studies to test the model in a larger population are ongoing. We propose that this model (and similarly derived models) can be implemented in clinical planning algorithms to improve the efficiency and cost of stem cell collection by apheresis. Acknowledgments: We would like to acknowledge and the nurses and staff of the apheresis unit and the stem cell and flow cytometry laboratories at the Hospital of the University of Pennsylvania for their contributions. Figure 1. Figure 1. Disclosures No relevant conflicts of interest to declare.


Blood ◽  
2016 ◽  
Vol 128 (22) ◽  
pp. 4731-4731
Author(s):  
H. Elizabeth Broome ◽  
Han-Inge Bengtsson ◽  
Laura Stephens ◽  
Lisa Palm

Abstract Introduction: Devices such as the CellaVision® DM96 (CellaVision AB, Lund, Sweden) locate and image nucleated cells on blood smears. Using image recognition software, the DM96 also pre-classifies those cells into differential categories similar to the most complex hematology analyzers. We compared the cell counts, differential counts and flagging information gained from a complex hematology analyzer, the XE5000 (Sysmex, Kobe, Japan), with information from a minimal hematology analyzer (Sysmex PocHi) plus the DM96. We found that the cell counts, differential and flagging capabilities are similar, but the PocHi plus DM96 advantages include allowing remote review of the blood smear. Methods: 210 blood samples, selected for various abnormalities, had complete blood counts with automated differentials produced by a Sysmex XE5000 hematology analyzer. These results were compared with cell counts from the Sysmex PocHi hematology analyzer, their 100-cell DM96 post reclassification differentials, and with DM96 pre-classification differentials using standard regression analyses and Rumke 95% confidence intervals (CI) as calculated using the Clopper-Pearson method. Flagging by the XE5000 for immature granulocytes (IG's) and for blasts/abnormal cells was compared to the DM96 pre-classification using truth tables with the DM96 post reclassification as the gold standard. The following translations were used to compare flagging: IG's > 2 for either post reclassification DM96 differential, XE5000 or the DM96 pre-classification differential; Any blast cells on the manual differential were compared to XE5000 flags WBC Abn Scg; NRBC Abn Scg; Blasts?; Atyp LY?; Abn Ly/ L_Bl? and to DM96 pre-classification % Blasts > 0%; unidentified cells >3%. . Results: Non-differential blood count parameters including white blood count, red blood count, hemoglobin, mean corpuscular volume (MCV), and platelet count showed excellent correlation between the PocHi and the XE5000 with R2>0.95. Differential-dependent blood count parameters including neutrophils, lymphocytes, monocytes, eosinophils, basophils and immature granulocytes showed excellent correlation between the XE5000 and pre-classification DM96 with R2>0.95. Nucleated red cells also showed excellent correlation between the XE5000 and the DM96 with R2>0.85. For blasts/abnormal cells, the DM96 showed 100% sensitivity and 40% specificity with 0% false negatives. The XE5000 showed 93% sensitivity and 19% specificity with 3% false negative. Two of the false negatives were shared by both instruments and were 1% blasts. Of the three false negatives with the XE5000 that were true positives with the DM96, two had 1% blasts while one had 2% blasts. For immature granulocytes (IG's), the XE5000 showed 94% sensitivity and 79% specificity with 2% false negatives. The DM96 showed 85% sensitivity and 95% specificity with 4% false negatives. All of the false negatives were for IG's < 5% Conclusions: Pairing the DM96 or a similar imaging instrument with a relatively inexpensive hematology analyzer, such as those commonly used in physician office laboratories, would provide all of the information available from expensive, complex hematology analyzers in high throughput laboratories AND allow remote review of the blood smear findings by experts. Disclosures Broome: CellaVision: Consultancy, Research Funding. Bengtsson:CellaVision AB: Employment, Equity Ownership. Palm:CellaVision: Employment, Equity Ownership.


2017 ◽  
Vol 38 (2) ◽  
pp. 232-237 ◽  
Author(s):  
Pablo Burraco ◽  
Francisco Miranda ◽  
Alejandro Bertó ◽  
Lola A. Vazquez ◽  
Ivan Gomez-Mestre

Assessments of amphibian immune state have been commonly made through indirect methods like phytohemagglutinin (PHA) injections, or by direct methods like cell counts from blood smears. Here we validate a simple method to assess immune responses in amphibians by means of flow cytometry with a fluorescent lipophilic dye (3,3′ Dipentyloxacarbocyanine), which removes the need for specific antibodies. We experimentally altered the immunological state ofPelobates cultripestadpoles by exposing some to exogenous corticosterone. We then determined the immune state of each tadpole through both blood smears and flow cytometry. We found that both techniques showed similar patterns of the proportion of white blood cells. Once validated, flow cytometry also allowed quantitation of changes in absolute number of white cells. We discuss the suitability of both techniques attending to the accuracy of each technique, body size requirements, or the tractability in field studies.


Blood ◽  
2004 ◽  
Vol 104 (11) ◽  
pp. 4784-4784
Author(s):  
Fuensanta Millá ◽  
Angels Barberá ◽  
Albert Oriol ◽  
Tomas Navarro ◽  
Jordi Juncà ◽  
...  

Abstract Introduction and objectives. Flow-cytometry based automated blood cell counters measure the volume (V), conductivity (C) and light scatter (S) of cells and make available these values for each subpopulation of white blood cells. Although differences in V, C and S among several lymphoproliferative disorders, reactive lymphocytes and normal lymphocytes have been described, the ability to use this this information to detect lymphoproliferative disorders has not been defined. Methods. We registered VCS data of all consecutive cases of lymphocytosis (lymphocytes &gt; 3.5x10e9/l) detected in routine laboratory testing during 50 non-consecutive days. Lymphocytes were evaluated morphologically, immunophenotypically and by conventional cytogenetics if necessary and the patients were evaluated clinically to document diagnosis adequately. Discriminant analisys modelling was used to assess the ability to predict diagnosis of VCS data. Results. 202 cases of lymphocytosis were detected in 120 males and 82 females, mean age 53 years (SD 16). Patients were considered to have normal lymphocytes (N=102, 50%), to present a reactive lymphocytosis (N=43, 21%, 20 of them HIV infected patients) or achieved a final diagnosis of lymphoproliferative disorder (N=57, 28%, 43 of them CLL). The mean volume of CLL lymphocytes was significantly lower than that of normal and reactive lymphocytes (p=0.009) and so was light scatter (p=0.018). When mean VCS values and their standard deviations were included in a discriminant analysis model, a unique function adequately classified 166/189 cases (87%) as CLL versus reactive or normal. Sensitivity and specificity were 73% and 92% respectively and false positive and false negative cases were 26% and 8% respectively. Inclusion of a second discriminant function did not improve significantly the predictive power of the model. Conclusion, VCS data from flow-cytometry based automated blood cell counters can be used to differentiate CLL from normal or reactive lymphocytes by simple discriminant analysis classification.


2000 ◽  
Vol 46 (2) ◽  
pp. 242-247 ◽  
Author(s):  
Reinhard Ziebig ◽  
Andreas Lun ◽  
Pranav Sinha

Abstract Background: The counting of leukocytes and erythrocytes in cerebrospinal fluid (CSF) is still performed microscopically, e.g., using a chamber in most laboratories. This requires sufficient practical experience, is time-consuming, and may constitute a problem in emergency diagnostics. Specific automated systems for CSF cell counting are not available at present. Methods: We tested the hematology analyzer CellDyn 3500 (CD) and the urine flow cytometer UF-100 (UF), which are not designed for CSF analysis. We studied &gt;104 samples with both analyzers, and the counts obtained were compared with the reference method (Fuchs-Rosenthal chamber). Results: Good linearity in the medically relevant range of 15 × 106 to 1000 × 106 leukocytes/L and a high degree of within-run accuracy were seen for both analyzers. Cell counting on the UF was excellent, especially when low cell counts were encountered (CV, 4.9% compared with 28% observed for the CD). Method comparison showed that identical results could be detected for a majority of the count pairs. For a few samples, there was a discrepancy between the results from the analyzers and the counting chamber. In most cases, these were CSF samples containing a high proportion of lymphocytes. For these samples, the CD result led to a false-positive high leukocyte count, and on the UF these cells were not allocated to the leukocyte population, thus leading to false-negative counts. Conclusions: Both analyzers should not be used for CSF cell counting in all cases at present. However, once the technical and software problems have been solved, routine use of the two analyzers for CSF analysis should be seriously contemplated.


2017 ◽  
Vol 142 (1) ◽  
pp. 83-88 ◽  
Author(s):  
Oh Joo Kweon ◽  
Mi-Kyung Lee ◽  
Hye Ryoun Kim

Context.— In the XN series of hematology analyzers (Sysmex, Kobe, Japan), the probability of the presence of abnormal cells is indicated by flags based on Q values. Objective.— To evaluate the Q value performance of the Sysmex XN-20 modular analyzer. Design.— The interinstrumental concordance, intrainstrumental precision, and diagnostic accuracy of Q values, with tested flags of “blasts/abnormal lymphocytes,” “atypical lymphocytes,” and “blasts,” were investigated. Results.— Absolute concordance rates in flagging between 2 analyzers ranged from 69.8% to 80.8%, and κ values ranged from 0.43 to 0.61. In samples with absolute related cell counts lower than 100/μL, the values ranged from 0.31 to 0.52. For intrainstrumental precision, standard deviations ranged from 4.8 to 23.9 for the blasts/abnormal lymphocytes, from 18.7 to 59.1 for the blasts, and from 11.0 to 23.0 for the atypical lymphocytes. Using a default Q value cutoff, diagnostic accuracy values based on the area under the curve, sensitivity, and specificity were, respectively, 0.910, 90.9%, and 72.2% for blasts/abnormal lymphocytes; 0.927, 84.9%, and 89.8% for blasts; and 0.865, 74.4%, and 84.9% for atypical lymphocytes. The diagnostic accuracy of Q values was much lower in samples with absolute related cell counts lower than 100/μL than in those 100/μL or higher. Conclusions.— Q values of the Sysmex XN-20 analyzer were found to be imprecise and irreproducible, especially with samples containing a small number of pathologic cells. Adjustments in the Q value threshold may help in the detection of these cells.


2019 ◽  
Vol 64 (1) ◽  
pp. 66-72
Author(s):  
V. S. Kozyreva ◽  
A. N. Shilova ◽  
O. S. Shkoda

Background. Immunological and infectious safety of blood components is considered to be a key condition for high-quality transfusion therapy. The progress of blood filtration methods contributes to the development of methods for the validation of residual leukocyte control in blood products.The aim of the study was to compare the efficiency of flow cytometer with hematology analyzer for counting residual leukocytes in blood productsMethods. In this study, we compared the efficiency of two analytical instruments for counting residual leukocytes in 191 blood plasma samples: a flow cytometer (Navios Beckman Coulter) with a LeukoSure commercial reagent kit and a Sysmex XT4000i hematology analyzer.Results. All the samples under investigation met technical regulation requirements. Most of the samples were characterized by a significantly low amount of residual leukocytes, which fact presented a particular scientific interest. The use of a Navios Beckman Coulter flow cytometer and a commercial reagent kit allowed us to detect 15 or lower cells per μL in 83 % of the samples. The use of a Sysmex XT- 4000i automatic hematology analyzer for the calculation of residual white blood cells in this range proved to be limited due to the sensitivity of the device and the absence of certified reference materials with a low white blood cell count.Conclusion. Our results show that a Navios Beckman Coulter flow cytometer with a commercial reagent kit is suitable for measuring residual leukocytes in blood plasma. This instrument is most appropriate for samples with a minimum number of cells. A significant variability of the amount of residual white blood cells in blood plasma confirms the importance of inspecting the content of leukocytes in all blood components.


Transfusion ◽  
2019 ◽  
Vol 60 (1) ◽  
pp. 155-164 ◽  
Author(s):  
Richard Alejo Blanco ◽  
Chloe Cavagnetto ◽  
Laura Willmott ◽  
Elif Aydogdu ◽  
Nicola Akinyemi ◽  
...  

2022 ◽  
Vol 8 (4) ◽  
pp. 265-273
Author(s):  
Deepa K Vijayan ◽  
Jiby Krishna K G ◽  
Dinimol Danniel ◽  
Ashily Shaji ◽  
Jojo Mathew ◽  
...  

: Impedance technology was a revolution in the history of Hematology. Mispa Count X is the first indigenous 3-part hematology analyzer in India, which works on the principle of impedance technology. : Performance evaluation of Mispa Count X.: The analyzer produces the measurement results of 18 parameters with throughput of 60 samples per hour. Mispa Count X was compared with benchmark analyzers Coulter DxH 800 and Sysmex XN 1000 to validate its performance. : Mispa Count X exhibited a wide linearity range for WBC, RBC, platelet and hemoglobin. The carry over for WBC, RBC, PLT and Hb was estimated and found to be well within the acceptable limits. The r values (&#62; 0.90) and bias estimation of Mispa Count X on comparing with Coulter DxH 800 and Sysmex XN 1000 were acceptable, except for mid cell counts and for MPV. Mispa Count X exhibited good precision with an acceptable CV% (&#60; 10%). The primary parameters of the stored samples were stable at room temperature for 24 hours. : So we conclude our study by proving that the Mispa Count X would be an affordable-reliable alternative for Indian healthcare sector instead of expensive imported hematology analyzers.


Sign in / Sign up

Export Citation Format

Share Document